Using advanced MRI to understand how Filgotinib relieves pain in rheumatoid arthritis

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to explore the mechanisms behind the analgesic effects of Filgotinib in patients with rheumatoid arthritis (RA). By utilizing 7 Tesla MRI brain imaging, the researchers will investigate how central nervous system pathways and peripheral inflammation contribute to pain relief. The study will focus on patients who have been prescribed Filgotinib, assessing both brain connectivity and inflammatory markers to better understand the rapid onset of pain relief associated with this treatment. The findings could provide insights into the complex nature of pain in RA and improve therapeutic strategies.

Why it matters

Who can join: the full rules

Inclusion Criteria:

Patients with moderate to severe active RA who have been prescribed filgotinib in line with the Summary of Product Characterisation and are:

* Adults ≥18 years \< 75 years.
* Right-handed (to reduce neuroimaging heterogeneity).

Exclusion Criteria:

* Inability to provide written informed consent.
* Severe physical impairment (e.g. blindness, deafness, paraplegia).
* Pregnant or breast feeding.
* Severe claustrophobia precluding MRI.
* Contraindications to MRI.
* Major confounding neurological disease including MS, Stroke, Traumatic Brain Injury.
* Previous targeted synthetic (e.g. baricitinib, tofacitinib) DMARD exposure for RA.

Where it's running

• Neil Basu
  Glasgow, United Kingdom Recruiting

Study contacts

• Principal investigator: Neil Basu, MD, PhD — University of Glasgow
• Study coordinator: Maxine Arnott
• Email: maxine.arnott@glasgow.ac.uk
• Phone: 0141 330 8388

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Better After Choosing: Filgotinib versus TNF inhibitor options for rheumatoid arthritis

  This trial will test whether letting adults with active rheumatoid arthritis choose between the oral JAK inhibitor filgotinib or a TNF-blocking biologic leads to higher treatment satisfaction compared with being randomly assigned to one of those treatments.

  Recruiting Phase 4 Rheumatology Research Center Northern Netherlands · Leeuwarden · NCT04985435

• GenAI-assisted RA bone erosion risk and DMARD choice

  This study tests whether GenAI-based decision support can help doctors assess rheumatoid arthritis bone erosion risk and pick DMARDs for newly diagnosed inpatients.

  Recruiting Guang'anmen Hospital of China Academy of Chinese Medical Sciences · Beijing, Beijing Municipality · NCT07914907

• Pain patterns in rheumatic diseases: see if pain works differently in patients and healthy people

  This observational study tests how pain is experienced and measured in people with rheumatic diseases compared with healthy volunteers.

  Recruiting National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT07829497

• Telitacicept for difficult-to-treat rheumatoid arthritis

  This study tests whether adding telitacicept to standard therapy helps adults with hard-to-treat rheumatoid arthritis see better control of their symptoms.

  Recruiting Phase 2 Peking University People's Hospital · Hefei, Anhui and 46 other locations · NCT07796516

• PTC844 in people with active rheumatoid arthritis

  This study tests whether PTC844 is safe and how it behaves in the body compared with placebo for people with active rheumatoid arthritis.

  Recruiting at 6 sites Phase 2 PTC Therapeutics · Chandler, Arizona and 25 other locations · NCT07779616

• First-in-human test of CND319 in healthy people and people with rheumatic diseases

  This early study tests whether CND319 is safe and tolerable and whether it shows any signs of activity in healthy adults and in people with rheumatoid arthritis or Sjogren's syndrome.

  Recruiting Phase 1 Candid Therapeutics · Melbourne, Victoria · NCT07712939

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.